RiconPharma has acquired a cGMP pharmaceutical manufacturing company in Fairfield, NJ to be called Mirror Pharmaceuticals LLC. The 32,000-sq.-ft. facility manufactures solid oral products and is currently manufacturing magnesium oxide tablets, sodium bi-carbonate tablets, sodium chloride tablets, and percogesic tablets (private label).

This acquisition adds seven approved ANDAs and two more pending ANDAs. RiconPharma will manage Mirror, which will file several ANDAs that are being developed by RiconPharma.

The facility is DEA-Licensed to manufacture schedule II-V drug products and features the following capabilities: wet granulation and drying capabilities, dry granulation, direct compression, different size blenders, Fitz mills, tableting machines, coating machine (to be installed and qualified), encapsulation machines, packaging lines, and QC/Analytical Labs.